Skeletal disorders

Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results

Retrieved on: 
Wednesday, August 4, 2021

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2021.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2021.
  • Completed enrollment of the Phase 3 LAVENDER study evaluating trofinetide for the treatment of Rett syndrome, with top-line results expected in the fourth quarter of 2021.
  • Initiated a Phase 2 study of ACP-044 for pain associated with osteoarthritis in the second quarter of 2021.
  • Acadia management will review its second quarter financial results and operations via conference call and webcast today at 4:30 p.m. Eastern Time.

Treace to Report Second Quarter 2021 Financial Results on August 5, 2021

Retrieved on: 
Tuesday, July 27, 2021

PONTE VEDRA, Fla., July 27, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (Treace) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced that it will release financial results for the second quarter of 2021 after the close of trading on Thursday, August 5, 2021.

Key Points: 
  • PONTE VEDRA, Fla., July 27, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (Treace) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced that it will release financial results for the second quarter of 2021 after the close of trading on Thursday, August 5, 2021.
  • Company management will host a conference call to discuss financial results beginning at 4:30 p.m.
  • A live and archived webcast of the event will be available on the Companys investors relations website at https://investors.treace.com/ .
  • Treace Medical Concepts is a commercial-stage orthopaedic medical device company with the goal of advancing the standard of care for the surgical management of bunion deformities.

Studies Show New Joint Support Formula Features "Nature's Best Ingredients" to Reduce Pain, Adding Cushion, Flexibility

Retrieved on: 
Tuesday, July 27, 2021

"Our Joint Support formula covers the whole gamut of joint pain caused by either lack of nutrients, pro-inflammatory effects, immune-related joint destruction or due to deposit of uric acid crystals."

Key Points: 
  • "Our Joint Support formula covers the whole gamut of joint pain caused by either lack of nutrients, pro-inflammatory effects, immune-related joint destruction or due to deposit of uric acid crystals."
  • In turn, this reduces pain while improving joint function, particularly related to symptoms from chronic knee pain and joint arthritis1,2.
  • Joint Support also contains a proprietary Hyaluronic Acid which researchers have said is a "remarkable natural lubricant" for patients with knee osteoarthritis5.
  • Undenatured type II collagen (UC-II) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteers.J Int Soc Sports Nutr.

Global Psoriatic Arthritis Epidemiology 10-year Forecasts 2020-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 26, 2021

The disease epidemiology covered in the report provides historical and forecasted Psoriatic Arthritis epidemiology segmented as the Prevalent cases of Psoriatic Arthritis, Diagnosed cases of Psoriatic Arthritis, Gender-specific cases of Psoriatic Arthritis, Age-specific cases of Psoriatic Arthritis and Severity-specific Prevalence of Psoriatic Arthritis.

Key Points: 
  • The disease epidemiology covered in the report provides historical and forecasted Psoriatic Arthritis epidemiology segmented as the Prevalent cases of Psoriatic Arthritis, Diagnosed cases of Psoriatic Arthritis, Gender-specific cases of Psoriatic Arthritis, Age-specific cases of Psoriatic Arthritis and Severity-specific Prevalence of Psoriatic Arthritis.
  • The report provides the segmentation of the Psoriatic Arthritis epidemiology by total prevalent cases of Psoriatic Arthritis in the 7MM.
  • The report provides the segmentation of the Psoriatic Arthritis epidemiology by age-specific cases of Psoriatic Arthritis in the 7MM.
  • The report provides the segmentation of the Psoriatic Arthritis epidemiology by the severity-specific prevalence of Psoriatic Arthritis in the 7MM.

Biosplice Publishes Phase 2B Lorecivivint Analysis Showing Clinically Meaningful Benefits to Knee Osteoarthritis Patients

Retrieved on: 
Thursday, July 22, 2021

SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the publication of a post-hoc analysis of its successful Phase 2b knee osteoarthritis clinical trial in Rheumatology and Therapy. Biosplice showed that study subjects dosed with 0.07 mg lorecivivint were over two times more likely to meet the criteria for OMERACT-OARSI Strict Response, a measure that includes 50% improvement in pain or function, than those on placebo at 12 weeks. Further, this response was maintained until the end of the study at 24 weeks.

Key Points: 
  • The importance of this analysis is that we are able to highlight the magnitude of the superiority of lorecivivint treatment for knee OA pain and function over placebo, said Biosplice Chief Medical Officer, Yusuf Yazici, MD.
  • While our successful Phase 2b study already demonstrated that lorecivivint significantly outperformed placebo in daily pain measurements out to six months, this further analysis sheds new light on the high potential of lorecivivint to relieve osteoarthritic patient suffering.
  • These confirmatory Phase 3 clinical trials ( NCT04385303 and NCT03928184 ) are further evaluating the impact of lorecivivint on knee osteoarthritis pain, function, and structure and have been modeled after Biosplices successful Phase 2b trial.
  • As reported earlier in the primary analysis of the Phase 2b study results, safety findings were similar between lorecivivint and placebo.

HSS Research Reveals New Insights into Racial Disparities in Revision Total Knee Replacement

Retrieved on: 
Wednesday, July 21, 2021

Now, researchers at Hospital for Special Surgery (HSS) have examined racial disparities separately for aseptic and septic revision total knee replacement using data from three large states.

Key Points: 
  • Now, researchers at Hospital for Special Surgery (HSS) have examined racial disparities separately for aseptic and septic revision total knee replacement using data from three large states.
  • In addition to being Black, other factors associated with a higher risk of septic revision total knee replacement were diabetes, obesity, renal disease, COPD, inflammatory arthritis, surgical site complications, Medicaid insurance and low hospital total knee replacement volume.
  • Similarly, for aseptic revision, additional risk factors were male sex, workers' compensation insurance and low hospital total knee replacement volume.
  • Parks and colleagues are currently conducting further research to look for a relationship between revision total knee replacement risk, hospital volume and annual volume by surgeon to see if they can learn more about racial disparities.

Osteoarthritis starts earlier than you think

Retrieved on: 
Tuesday, July 20, 2021

I often feel like a bad mother because of osteoarthritis (OA), says the Vancouver resident, who was diagnosed with the disease at age 30.

Key Points: 
  • I often feel like a bad mother because of osteoarthritis (OA), says the Vancouver resident, who was diagnosed with the disease at age 30.
  • This important study demonstrates that osteoarthritis is most certainly not an older persons disease, says Trish Barbato, President and CEO of the Arthritis Society.
  • The disease starts much earlier than we think, and when it strikes a younger adult, it can overshadow their entire life.
  • They deserve earlier diagnosis and effectiveness interventions, along with more support for research and innovation that will ultimately extinguish the impacts of this disease.

Dr. Robert Moghim to Participate in Clinical Trial for Knee Pain Using Freedom Peripheral Nerve Stimulator

Retrieved on: 
Thursday, July 15, 2021

DENVER, July 15, 2021 /PRNewswire/ --Dr. Robert Moghim at Colorado Pain Care has recently been approved to participate in a clinical trial on Peripheral Nerve Stimulation for Knee Pain.

Key Points: 
  • DENVER, July 15, 2021 /PRNewswire/ --Dr. Robert Moghim at Colorado Pain Care has recently been approved to participate in a clinical trial on Peripheral Nerve Stimulation for Knee Pain.
  • This study is designed to assess the effectiveness of the Freedom Peripheral Nerve Stimulator (PNS) System for treating chronic knee pain caused by osteoarthritis.
  • Dr. Moghim will be enrolling 10 participants for this study that is expected to last 2 years.
  • The results are intended to help people with arthritic knee pain in the future.

$50,000 OREF/AAOS Injectable Orthobiologics of Knee Osteoarthritis Grant Awarded

Retrieved on: 
Monday, July 12, 2021

Rodeo, MD, FAAOS, of the Hospital for Special Surgery (HSS) in New York City has been awarded the first OREF/AAOS Injectable Orthobiologics of Knee Osteoarthritis Grant.

Key Points: 
  • Rodeo, MD, FAAOS, of the Hospital for Special Surgery (HSS) in New York City has been awarded the first OREF/AAOS Injectable Orthobiologics of Knee Osteoarthritis Grant.
  • Funding for this grant was made possible through the OREF/AAOS Clinical Research Gaps Fund with contributions from the American Academy of Orthopaedic Surgeons (AAOS) and individual donors.
  • The $50,000 grant is the first to be awarded as part of a strategic partnership between OREF and AAOS which aims to help narrow the gap between clinical research funding and prioritized clinical research needs in musculoskeletal care, including orthobiologics.
  • This particular study of the use of an injectable orthobiologic, PRP, of a common knee ligament injury may lend insight into treatments to either prevent or minimize the later development of osteoarthritis of the knee.

Worldwide Osteoarthritis Treatment Industry to 2029 - by Class of Drug, Anatomy, Route of Administration, Distribution Channel, Purchase Mode and Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021

The global osteoarthritis treatment market is projected to grow at a CAGR of 9.0%.

Key Points: 
  • The global osteoarthritis treatment market is projected to grow at a CAGR of 9.0%.
  • However osteoarthritis can damage any joint, the disorder most commonly affects joints in your hands, knees, hips & spine.
  • What is the key impact of Covid-19 over market revenues and market determinants in the Osteoarthritis Treatment Market?
  • Who are the key players in the Osteoarthritis Treatment Market and what are their key product categories and strategies?